The nervous system and diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 951-968

  Freeman, Roy ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971016692     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (317)

1. Marchal de Calvi CJ. Recherches sur les accidents diabetiques. P Asselin, 1894.
2. Marton MM. Diabetic neuropathy: a clinical study of 150 cases. Brain 1953;76:594-624.
3. Pavy FW. Introductory address to the discussion on the clinical aspect of glycosuria. Lancet 1885;2:1033-1035.
4. Leyden E. Beitrage zur Klinik des Diabetes Mellitus. Wein Med Wochenschr 1893;43:926.
5. Jordan WR. Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936;57:307-366.
6. Treusch JV. Diabetic neuritis: a tentative working classification. Proc Mayo Clin 1945;20:393-402.
7. Goodman JI, Barmoel S, Frankel L. The diabetic neuropathies. Springfield, MA: Charles C Thomas Publisher, 1953.
8. Locke S. The peripheral nervous system in diabetes mellitus. Diabetes 1964;13:307-311.
9. Bruyn GW, Garland H. Neuropathies of endocrine origin. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. Amsterdam: North-Holland Publishing, 1970:29-71.
10. Dyck PJ, Karnes J, O'Brien PC. Diagnosis, staging, and classification of diabetic neuropathy and association with other complications. In: Dyck PJ, Thomas PK, Asbury AK, eds. Diabetic neuropathy. Philadelphia: WB Saunders, 1987:36-44.
11. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Dyck PJ, Thomas EH, Lambert RB, eds. Peripheral neuropathy. Philadelphia: WB Saunders, 1993:1219-1250.
12. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. [French]. Diabete Metab 1977;3:245-256.
13. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. . Engl J Med 1995;333:89-94.
14. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824.
15. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377-1384.
16. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989;38:1456-1461.
17. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care 1997;20:836-843.
18. Young MJ, Boulton AJ, Macleod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-154.
19. Effect of intensive diabetes therapy on the development and progression of neuropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial (DCCT) Research Group. Ann Intern Med 1995;122:561-568.
20. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39:1483-1488.
21. Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte, Italy: the Neuropathy Study Group of the Italian Society for the Study of Diabetes, Piemonte Affiliate. Diabetes Care 1993;16:456-461.
22. Waxman SG, Sabin TD. Diabetic truncal polyneuropathy. Arch Neurol 1981; 38:46-47.
23. Ellenberg M. Diabetic truncal mononeuropathy: a new clinical syndrome. Diabetes Care 1978;1:10-13.
24. Longstreth GF, Newcomer AD. Abdominal pain caused by diabetic radiculopathy. Ann Intern Med 1977;86:166-168.
25. Sun SF, Streib EW. Diabetic thoracoabdominal neuropathy: clinical and electrodiagnostic features. Ann Neurol 1981;9:75-79.
26. Heinrichs RW, Moorhouse JA. Touch-perception thresholds in blind diabetic subjects in relation to the reading of Braille type. . Engl J Med 1969;280:72-75.
27. Stewart JD, McKelvey R, Durcan L, et al. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. . Neurol Sci 1996;142(1-2):59-64.
28. Boulton AJ, Armstrong WD, Scarpello JH, et al. The natural history of painful diabetic neuropathy-a 4-year study. Postgrad Med J 1983;59:556-559.
29. Said G, Slama G, Selva J. Progressive centripetal degeneration of axons in small fibre diabetic polyneuropathy. Brain 1983;106:791-807.
30. Dyck PJ, Lais A, Karnes JL, et al. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986;19:425-439.
31. Young RJ, Zhou YQ, Rodriguez E, et al. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986;35:192-197.
32. Gruener G, Dyck PJ. Quantitative sensory testing: methodology, applications, and future directions. . Clin Neurophysiol 1994;11:568-583.
33. Dyck PJ, Bushek W, Spring EM, et al. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 1987;10:432-440.
34. Edmonds ME. The diabetic foot: pathophysiology and treatment. Clin Endocrinol Metab 1986;15:889-916.
35. Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabet Med 1996;13[Suppl 1]:S12-S16.
36. Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996;13 [Suppl 1]:S6-S11.
37. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lowerextremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157-162.
38. Boulton AJ, Kubrusly DB, Bowker JH, et al. Impaired vibratory perception and diabetic foot ulceration. Diabet Med 1986;3:335-337.
39. Kumar S, Fernando DJ, Veves A, et al. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract 1991;13:63-67.
40. Shapiro SA, Stansberry KB, Hill MA, et al. Normal blood flow response and vasomotion in the diabetic Charcot foot. . Diabetes Complications 1998;12: 147-153.
41. Klenerman L. The Charcot joint in diabetes. Diabet Med 1996;13[Suppl 1]: S52-S54.
42. Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. . Neurol Neurosurg Psychiatry 1983;46:491-499.
43. Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974;23:418-423.
44. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 1988;11:34-40.
45. Blau RH. Diabetic neuropathic cachexia: report of a woman with this syndrome and review of the literature. Arch Intern Med 1983;143:2011-2012.
46. Jackson CE, Barohn RJ. Diabetic neuropathic cachexia: report of a recurrent case. . Neurol Neurosurg Psychiatry 1998;64:785-787.
47. Caravati CM. Insulin neuritis: a case report. Va Med Monthly 1933;59:745-746.
48. Ellenberg M. Diabetic neuropathy precipitating after institution of diabetic control. Am J Med Sci 1958;236:466.
49. Llewelyn JG, Thomas PK, Fonseca V, et al. Acute painful diabetic neuropathy precipitated by strict glycemic control. Acta Neuropathol (Berl) 1986;72: 157-163.
50. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996;39:329-335.
51. Dyck PJ, Lambert EH, Windebank AJ, et al. Acute hyperosmolar hyperglycemia causes axonal shrinkage and reduced nerve conduction velocity. Exp Neurol 1981;71:507-514.
52. Stewart JD, McKelvey R, Duran L, et al. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. Neurol Sci 1996;142:59-64.
53. Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000;23:37-43.
54. Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003;27:465-470.
55. Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002;59:758-765.
56. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus [See comments]. Arch Neurol 1995;52:1053-1061.
57. Younger DS, Rosoklija G, Hays AP, et al. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996;19:722-727.
58. Uncini A, De Angelis MV, Di Muzio A, et al. Chronic inflammatory demyelinating polyneuropathy in diabetics: motor conductions are important in the differential diagnosis with diabetic polyneuropathy. Clin Neurophysiol 1999;110:705-711.
59. Zorrilla E, Kozak GP. Ophthalmoplegia in diabetes mellitus. Arch Intern Med 1967;67:968-976.
60. Ross AT. Recurrent cranial nerve palsies in diabetes mellitus. Neurology 1962;12:180-185.
61. Barricks ME, Traviesa DB, Glaser JS, et al. Ophthalmoplegia in cranial arteritis. Brain 1977;100:209-221.
62. Asbury AK, Fields HL. Pain due to peripheral nerve damage: an hypothesis. Neurology 1984;34:1587-1590.
63. Breen LA, Hopf HC, Farris BK, et al. Pupil-sparing oculomotor nerve palsy due to midbrain infarction. Arch Neurol 1991;48:105-106.
64. Nadeau SE, Trobe JD. Pupil sparing in oculomotor palsy: a brief review. Ann Neurol 1983;13:143-148.
65. Asbury AK, Aldredge H, Hershberg R, et al. Oculomotor palsy in diabetes mellitus: a clinicopathological study. Brain 1970;93:555-566.
66. Jørgensen MB, Buch NH. Studies on the sense of smell and taste in diabetics. Acta Otolaryngol 1961;53:539-545.
67. Pavan PR, Aiello LM, Wafai MZ, et al. Optic disc edema in juvenile-onset diabetes. Arch Ophthalmol 1980;98:2193-2195.
68. Lubow M, Makley TA, Jr. Pseudopapilledema of juvenile diabetes mellitus. Arch Ophthalmol 1971;85:417-422.
69. Korczyn AD. Bell's palsy and diabetes mellitus. Lancet 1971;1:108-109.
70. Adour KK, Wingerd J. Idiopathic facial paralysis (Bell's palsy): factors affecting severity and outcome in 446 patients. Neurology 1974;24:1112-1116.
71. Bruns L. Ueber neuritische Lähmungen beim Diabetes Mellitus. Berl Klin Wochenschr 1890;27:509-515.
72. Garland H, Taverner D. Diabetic myelopathy. BMJ 1953;1:1405-1413.
73. Garland JT. Diabetic amyotrophy. BMJ 1955;2:1287-1290.
74. Coppack SW, Watkins PJ. The natural history of diabetic femoral neuropathy. . J Med 1991;79:307-313.
75. Calverley JR, Mulder DW. Femoral neuropathy. Neurology 1960;10:963-967.
76. Sullivan JF. The neuropathies of diabetes. Neurology 1958;8:243-249.
77. Williams IR, Mayer RF. Subacute proximal diabetic neuropathy. Neurology 1976;26:108-116.
78. Pascoe MK, Low PA, Windebank AJ, et al. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997;72:1123-1132.
79. Raff MC, Asbury AK. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus. . Engl J Med 1968;279:17-21.
80. Bastron JA, Thomas JE. Diabetic polyradiculopathy: clinical and electromyographic findings in 105 patients. Mayo Clin Proc 1981;56:725-732.
81. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999;53:2113-2121.
82. Asbury AK. Proximal diabetic neuropathy. Ann Neurol 1977;2:179-180.
83. Barohn RJ, Sahenk Z, Warmolts JR, et al. The Bruns-Garland syndrome (diabetic amyotrophy): revisited 100 years later. Arch Neurol 1991;48:1130-1135.
84. Casey EB, Harrison MJ. Diabetic amyotrophy: a follow-up study. BMJ 1972;1:656-659.
85. Hamilton CR, Jr., Dobson HL, Marshall J. Diabetic amyotrophy: clinical and electron microscopic studies in six patients. Am J Med Sci 1968;256:81-90.
86. Locke S, Lawrence DG, Legg MA. Diabetic amyotrophy. Am J Med 1963; 34:775-785.
87. Chokroverty S, Reyes MG, Rubino FA, et al. The syndrome of diabetic amyotrophy. Ann Neurol 1977;2:181-194.
88. Chokroverty S. Proximal nerve dysfunction in diabetic proximal amyotrophy: electrophysiology and electron microscopy. Arch Neurol 1982;39:403-407.
89. Chokroverty S. AAEE case report 13: diabetic amyotrophy. Muscle Nerve 1987;10:679-684.
90. Chokroverty S, Sander HW. AAEM case report 13: diabetic amyotrophy. Muscle Nerve 1996;19:939-945.
91. Root HF, Rogers MH. Diabetic neuritis with paralysis. . Engl J Med 1930; 202:1049-1053.
92. Hirsh LF. Diabetic polyradiculopathy simulating lumbar disc disease: report of four cases. . Neurosurg 1984;60:183-186.
93. Subramony SH, Wilbourn AJ. Diabetic proximal neuropathy: clinical and electromyographic studies. . Neurol Sci 1982;53:293-304.
94. Gilliatt RW, Willison RG. Peripheral nerve conduction in diabetic neuropathy. . Neurol Neurosurg Psychiatry 1962;25:11-18.
95. Chopra JS, Hurwitz LJ. Femoral nerve conduction in diabetes mellitus and chronic occlusive vascular disease. Electroencephalogr Clin Neurophysiol 1968; 25:399.
96. Lamontagne A, Buchthal F. Electrophysiological studies in diabetic neuropathy. . Neurol Neurosurg Psychiatry 1970;33:442-452.
97. Said G, Goulon-Goeau C, Lacroix C, et al. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559-569.
98. Said G, Elgrably F, Lacroix C, et al. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome. Ann Neurol 1997;41:762-770.
99. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52:1053-1061. 92a. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25(4):477-491.
100. Stewart JD. Diabetic truncal neuropathy: topography of the sensory deficit. Ann Neurol 1989;25:233-238.
101. Boulton AJ, Angus E, Ayyar DR, et al. Diabetic thoracic polyradiculopathy presenting as abdominal swelling. BMJ (Clin Res Ed) 1984;289:798-799.
102. Parry GJ, Floberg J. Diabetic truncal neuropathy presenting as abdominal hernia. Neurology 1989;39:1488-1490.
103. Kikta DG, Breuer AC, Wilbourn AJ. Thoracic root pain in diabetes: the spectrum of clinical and electromyographic findings. Ann Neurol 1982;11:80-85.
104. Streib EW, Sun SF, Paustian FF, et al. Diabetic thoracic radiculopathy: electrodiagnostic study. Muscle Nerve 1986;9:548-553.
105. Dolman CL. The morbid anatomy of diabetic neuropathy. Neurology 1963;13: 135-142. 98a. Lauria G, McArthur JC, Hauer PE, et al. Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy. . Neurol Neurosurg Psychiatry 1998;65:762-766.
106. Fraser DM, Campbell IW, Ewing DJ, et al. Mononeuropathy in diabetes mellitus. Diabetes 1979;28:96-101.
107. Jung Y, Hohmann TC, Gerneth JA, et al. Diabetic hand syndrome. Metabolism 1971;20:1008-1015.
108. de Carvalho MA, Matias T, Evangelista T, et al. Bilateral phrenic nerve neuropathy in a diabetic patient. Eur J Neurol 1996;3:481-482.
109. Low PA. Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 1987;10:121-128.
110. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46[Suppl 2]:S31-S37.
111. Greene DA, Lattimer SA. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation. . Clin Invest 1983; 72:1058-1063.
112. Greene DA, Yagihashi S, Lattimer SA, et al. Nerve Na+-K+-ATPase, conduction and myoinositol in the insulin deficient BB-rat. Am J Physiol 1984; 247:E534-E539.
113. Stevens MJ, Lattimer SA, Kamijo M, et al. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993;36:608-614.
114. Greene DA, Mackway AM. Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Diabetes 1986;35:1106-1108.
115. Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. . Engl J Med 1988;319:542-548.
116. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-596.
117. Greene DA, Lewis RA, Lattimer SA, et al. Selective effect of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozotocin-diabetic rat. Diabetes 1983;31:573-578.
118. Hale PJ, Nattrass M, Silverman SH, et al. Peripheral nerve concentrations of glucose, fructose, sorbitol and myoinositol in diabetic and non-diabetic patients. Diabetologia 1987;30:464-467.
119. Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997;46[Suppl 2]:S90-S93.
120. Cameron NE, Cotter MA, Robertson S. Essential fatty acid diet supplementation: effects on peripheral nerve and skeletal muscle function and capillarization in streptozocin-induced diabetic rats. Diabetes 1991;40:532-539.
121. Julu PO. Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetic rats. . Diabet Complications 1988;2:185-188.
122. Cameron NE, Cotter MA, Dines KC, et al. The effects of evening primrose oil on nerve function and capillarization in streptozotocin-diabetic rats: modulation by the cyclo-oxygenase inhibitor flurbiprofen. Br J Pharmacol 1993;109:972-979.
123. Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46 [Suppl 2]:S38-S42.
124. Cameron NE, Cotter MA, Archibald V, et al. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994;37: 449-459.
125. Cotter MA, Love A, Watt MJ, et al. Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 1995;38:1285-1294.
126. Bravenboer B, Kappelle AC, Hamers FP, et al. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocininduced diabetic rat. Diabetologia 1992;35:813-817.
127. Cotter MA, Cameron NE. Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity. Naunyn Schmiedebergs Arch Pharmacol 1995;351:630-635.
128. Cameron NE, Cotter MA, Maxfield EK. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993;36:299-304.
129. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. . Clin Invest 1995;96:1159-1163.
130. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18:1160-1167.
131. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835-1843.
132. Brownlee M. Nonenzymatic glycosylation of macromolecules: prospects of pharmacologic modulation. Diabetes 1992;41[Suppl 2]:57-60.
133. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. . Clin Invest 1991;87:432-438.
134. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992;41:26-29.
135. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993;42:221-232. 129 Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-2588.
136. Kim J, Rushovich EH, Thomas TP, et al. Diminished specific activity of cytosolic protein kinase C in sciatic nerve of streptozocin-induced diabetic rats and its correction by dietary myo-inositol. Diabetes 1991;40:1545-1554.
137. Roberts RE, McLean WG. Protein kinase C isozyme expression in sciatic nerves and spinal cords of experimentally diabetic rats. Brain Res 1997;754:147-156.
138. Cameron NE, Cotter MA, Jack AM, et al. Protein kinase C effects on nerve function, perfusion, Na(+),K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999;42:1120-1130.
139. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999;48:2090-2095.
140. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. Clin Invest 2003;112:1049-1057.
141. Obrosova IG, Li F, Abatan OI, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004;53:711-720.
142. Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. . Neurosci Res 1990;26:258-267.
143. Jakobsen J, Brimijoin S, Skau K, et al. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes 1981;30:797-803.
144. Apfel SC, Arezzo JC, Brownlee M, et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994; 634:7-12.
145. Schmidt RE, Dorsey DA, Beaudet LN, et al. Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. . Neuropathol Exp Neurol 2001;60:263-273.
146. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997;46[Suppl 2]:S43-S49.
147. Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984;107:935-950.
148. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991;261:E1-E8.
149. Cameron NE, Cotter MA, Ferguson K, et al. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na(+)-K(+)-ATPase activity, and vascular supply in STZ-D rats. Diabetes 1991;40:1652-1658.
150. Cameron NE, Cotter MA, Robertson S. Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 1993;30:46-48.
151. Low PA, Tuck RR, Dyck PJ, et al. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci U S A 1984;81:6894-6898.
152. Yao JK, Low PA. Improvement of endoneurial lipid abnormalities in experimental diabetic neuropathy by oxygen modification. Brain Res 1986;362: 362-365.
153. Woltman HW, Wilder RM. Diabetes mellitus: pathologic changes in the spinal cord and peripheral nerves. Arch Intern Med 1929;44:576-603.
154. Fagerberg S-E. Diabetic neuropathy. Acta Med Scand 1959;164[Suppl 345]: 1-81.
155. Fagerberg S-E. Neuropathie diabótique. World Neurol 1961;2:509-519.
156. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. . Neurol Neurosurg Psychiatry 1977;40:1072-1082.
157. Chopra JS, Hurwitz LJ, Montgomery DA. The pathogenesis of sural nerve changes in diabetes mellitus. Brain 1969;92:391-418.
158. Timperley WR, Boulton AJ, Davies-Jones GA, et al. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control. . Clin Pathol 1985;38:1030-1038.
159. Dyck PJ, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci U S A 1985;82:2513-2517.
160. Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987;37:20-28.
161. Malik RA, Veves A, Masson EA, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy. . Neurol Neurosurg Psychiatry 1992;55: 557-561.
162. Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia 1993;36: 454-459.
163. Giannini C, Dyck PJ. Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol 1994;36: 408-415.
164. Giannini C, Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995;37:498-504.
165. Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989;32:92-102.
166. Dyck PJ, Karnes JL, O'Brien P, et al. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986;19:440-449.
167. Dyck PJ, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy. Threedimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin Proc 1972;47:461-475.
168. Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain 1987;110:843-853.
169. Llewelyn JG, Thomas PK, Gilbey SG, et al. Pattern of myelinated fibre loss in the sural nerve in neuropathy related to type 1 (insulin-dependent) diabetes. Diabetologia 1988;31:162-167.
170. Greenbaum D, Richardson PC, Salmon MV, et al. Pathological observations on six cases of diabetic neuropathy. Brain 1964;87:201-214.
171. Olsson Y, Säve-Söderbergh J, Sourander P, et al. A patho-anatomical study of the central and peripheral nervous system in diabetes of early onset and long duration. Pathol Eur 1968;3:62-79.
172. Coërs C, Hildebrand J. Latent neuropathy in diabetes and alcoholism: electromyographic and histological study. Neurology 1965;15:19-38.
173. Chopra JS, Sawhney BB, Chakravorty RN. Pathology and time relationship of peripheral nerve changes in experimental diabetes. . Neurol Sci 1977;32:53-67.
174. Thomas PK, Lascelles RG. The pathology of diabetic neuropathy. . J Med 1966;35:489-509.
175. Vital C, Le Blanc M, Vallat JM, et al. [Ultrastructural study of peripheral nerve in 16 diabetics without neuropathy. Comparisons with 16 diabetic neuropathies and 16 non-diabetic neuropathies (author's transl)] [French]. Acta Neuropathol (Berl) 1974;30:63-72.
176. Vital C, Vallat JM, Le Blanc M, et al. [Peripheral neuropathies caused by diabetes mellitus. Ultrastructural study of 12 biopsied cases] [French]. . Neurol Sci 1973;18:381-398.
177. Asbury AK, Johnson PC. Pathology of peripheral nerve. Major Probl Pathol 1978;9:1-311. 168a. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25:477-491.
178. Dreyfus PM, Hakim S, Adams RD. Diabetic ophthalmoplegia: report of case, with postmortem study and comments on vascular supply of human oculomotor nerve. Arch Neurol Psychiatry 1957;77:337-349.
179. Weber RB, Daroff RB, Mackey EA. Pathology of oculomotor nerve palsy in diabetics. Neurology 1970;20:835-838.
180. Smith BE, Dyck PJ. Subclinical histopathological changes in the oculomotor nerve in diabetes mellitus. Ann Neurol 1992;32:376-385.
181. Appenzeller O, Richardson EP Jr. The sympathetic chain in patients with diabetic and alcoholic polyneuropathy. Neurology 1966;16:1205-1209.
182. Hensley GT, Soergel KH. Neuropathologic findings in diabetic diarrhea. Arch Pathol 1968;85:587-597.
183. Duchen LW, Anjorin A, Watkins PJ, et al. Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med 1980;92:301-303.
184. Olsson Y, Sourander P. Changes in the sympathetic nervous system in diabetes mellitus: a preliminary report. . Neurovasc Relat 1968;31:86-95.
185. Low PA, Walsh J: C, Huang CY, et al. The sympathetic nervous system in diabetic neuropathy: a clinical and pathological study. Brain 1975;98:341-356.
186. Kristensson K, Nordborg C, Olsson Y, et al. Changes in the vagus nerve in diabetes mellitus. Acta Pathol Microbiol Scand 1971;79[A]:684-685.
187. Britland ST, Young RJ, Sharma AK, et al. Vagus nerve morphology in diabetic gastropathy. Diabetic Med 1990;7:780-787.
188. Faerman I, Glocer L, Celener D, et al. Autonomic nervous system and diabetes: histological and histochemical study of the autonomic nerve fibers of the urinary bladder in diabetic patients. Diabetes 1973;22:225-237.
189. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. . Engl J Med 1993;329:977-986.
190. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-423.
191. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
192. Reichard P, Britz A, Carlsson P, et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). . Intern Med 1990;228:511-517.
193. Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. . Intern Med 1991;230:101-108.
194. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. . Engl J Med 1993;329:304-309.
195. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-622.
196. Eliasson SG. Properties of isolated nerve fibres from alloxanized rats. . Neurol Neurosurg Psychiatry 1969;32:525-529.
197. Does improved control of glycemia prevent or ameliorate diabetic polyneuropathy? Committee on Health Care Issues, American Neurological Association. Ann Neurol 1986;19:288-290.
198. Gregersen G. Diabetic neuropathy: influence of age, sex, metabolic control, and duration of diabetes on motor conduction velocity. Neurology 1967;17: 972-980.
199. Graf RJ, Halter JB, Halar E, et al. Nerve conduction abnormalities in untreated maturity-onset diabetes: relation to levels of fasting plasma glucose and glycosylated hemoglobin. Ann Intern Med 1979;90:298-303.
200. Porte D Jr, Graf RJ, Halter JB, et al. Diabetic neuropathy and plasma glucose control. Am J Med 1981;70:195-200.
201. Ward JD, Barnes CG, Fisher DJ, et al. Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1971;1:428-430.
202. Anonymous. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869-880.
203. Schmidt RE, Plurad SB, Olack BJ, et al. The effect of pancreatic islet transplantation and insulin therapy on experimental diabetic autonomic neuropathy. Diabetes 1983;32:532-540.
204. Schmidt RE, Plurad SB, Olack BJ, et al. The effect of pancreatic islet transplantation and insulin therapy on neuroaxonal dystrophy in sympathetic autonomic ganglia of chronic streptozocin-diabetic rats. Brain Res 1989;497: 393-398.
205. Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. . Engl J Med 1990;322:1031-1037.
206. Navarro X, Kennedy WR, Loewenson RB, et al. Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. Diabetes 1990;39:802-806.
207. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997;42:727-736.
208. Nusser J, Scheuer R, Abendroth D, et al. Effect of pancreatic and/or renal transplantation on diabetic autonomic neuropathy. Diabetologia 1991;34 [Suppl 1]:S118-S120.
209. Solders G, Wilczek H, Gunnarsson R, et al. Effects of combined pancreatic and renal transplantation on diabetic neuropathy: a two-year follow-up study. Lancet 1987;2:1232-1235.
210. Solders G, Tyden G, Persson A, et al. Improvement in diabetic neuropathy 4 years after successful pancreatic and renal transplantation. Diabetologia 1991; 34[Suppl 1]:S125-S127.
211. Trojaborg W, Smith T, Jakobsen J, et al. Effect of pancreas and kidney transplantation on the neuropathic profile in insulin-dependent diabetics with end-stage nephropathy. Acta Neurol Scand 1994;90:5-9.
212. Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy: a clinical and neurophysiological study. . Neurol Neurosurg Psychiatry 1981;44:991-1001.
213. Jaspan J, Maselli R, Herold K, et al. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 1983;2:758-762.
214. Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. . Engl J Med 1983;308:119-125.
215. Young RJ, Ewing DJ, Clarke BF. Acontrolled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983;32: 938-942.
216. Lewin IG, O'Brien IA, Morgan MH, et al. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 1984;26:445-448.
217. Martyn CN, Reid W, Young RJ, et al. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy: failure to improve abnormal nerve function. Diabetes 1987;36:987-990.
218. O'Hare JP, Morgan MH, Alden P, et al. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabet Med 1988;5:537-542. 209a. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs [Review]? Diabetes 1997;46 [Suppl 2]:S82-S89.
219. Gregersen G. Myoinositol supplementation. In: Dyck PJ, Thomas PK, Asbury AK, et al., eds. Diabetic neuropathy. Philadelphia: WB Saunders, 1987:188-189.
220. Mayhew JA, Gillon KR, Hawthorne JN. Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983;24:13-15.
221. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med 1990;7:319-323.
222. Jamal GA. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabet Med 1994;11:145-149.
223. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The Gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care 1993;16:8-15.
224. Zeigler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN). Diabetologia 1995;38: 1425-1433. 215a. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004;21:114-121.
225. Zeigler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac neuropathy in NIDDM patients: a 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997;20:369-373.
226. Apfel SC, Kessler JA, Adornato BT, et al. and the NGF Study Group. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.
227. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000;284:2215-2221.
228. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553-1579.
229. Said G, Goulon-Goeau C, Slama G, et al. Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus: a clinical and pathological study. . Engl J Med 1992;326:1257-1263.
230. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986;9:648-665.
231. Neil HA, Thompson AV, John S, et al. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med 1989;6:20-24.
232. Lloyd-Mostyn RH, Watkins PJ. Defective innervation of heart in diabetic autonomic neuropathy. BMJ 1975;3:15-17.
233. Bennett T, Hosking DJ, Hampton JR. Cardiovascular control in diabetes mellitus. BMJ 1975;2:585-587.
234. Ewing DJ, Campbell IW, Clarke BF. Heart rate changes in diabetes mellitus. Lancet 1981;1:183-186.
235. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. . J Med 1980;49:95-108.
236. O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. . J Med 1991; 79:495-502.
237. Rathmann W, Ziegler D, Jahnke M, et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993;10:820-824.
238. Sampson MJ, Wilson S, Karagiannis P, et al. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. . J Med 1990;75:635-646. 229a. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895-1901.
239. Frimodt-Moller C, Mortensen S. Treatment of diabetic cystopathy. Ann Intern Med 1980;92:327-328.
240. Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med 1980;92:321-323.
241. Ioanid CP, Noica N. Incidence and diagnostic aspects of the bladder disorders in diabetics. Eur Urol 1981;7:211-214.
242. Bradley WE. Diagnosis of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med 1980;92:323-326.
243. Appell RA, Whiteside HV. Diabetes and other peripheral neuropathies affecting lower urinary tract function. In: Krane RJ, Siroky MB, eds. Clinical neurourology. Boston: Little, Brown and Company, 1992:365-373.
244. McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia 1980;18:279-283.
245. Ellenberg M. Impotence in diabetes: the neurologic factor. Ann Intern Med 1971;75:213-219.
246. Kaiser FE, Korenman SG. Impotence in diabetic men. Am J Med 1988;85 [Suppl 5A]:147-152.
247. Hakim LS, Goldstein I. Diabetic sexual dysfunction. Endocrinol Metab Clin North Am 1996;25:379-400.
248. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. . Engl J Med 1992;326:90-94.
249. de Tejada IS, Goldstein I, Azadzoi K, et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. . Engl J Med 1989;320:1025-1030.
250. DeGroat WC, Booth AM. Physiology of male sexual function. Ann Intern Med 1980;92:329-331.
251. Krane RJ, Siroky MB. Neurophysiology of erection. Neurol Clin North Am 1981;8:91-102.
252. Ellenberg M. Sexual function in diabetic patients. Ann Intern Med 1980;92: 331-333.
253. Wegener M, Borsch G, Schaffstein J, et al. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990;8:23-36.
254. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:151-159.
255. Kassander P. Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum). Ann Intern Med 1958;48:797-812.
256. Vogelberg KH, Rathmann W, Helbig G. Sonographic examination of gastric motility in diabetics with autonomic neuropathy. Diabetes Res 1987; 5:175-179.
257. Brady PG, Richardson R. Gastric bezoar formation secondary to gastroparesis diabeticorum. Arch Intern Med 1977;137:1729.
258. Parkman HP, Schwartz SS. Esophagitis and gastroduodenal disorders associated with diabetic gastroparesis. Arch Intern Med 1987;147:1477-1480.
259. Loo FD, Palmer DW, Soergel KH, et al. Gastric emptying in patients with diabetes mellitus. Gastroenterology 1984;86:485-495.
260. Ogbonnaya KI, Arem R. Diabetic diarrhea: pathophysiology, diagnosis, and management. Arch Intern Med 1990;150:262-267.
261. Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993;68:691-702.
262. Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol 1999;94:2165-2170.
263. Schiller LR, Santa Ana CA, Schmulen AC, et al. Pathogenesis of fecal incontinence in diabetes mellitus: evidence for internal-anal-sphincter dysfunction. . Engl J Med 1982;307:1666-1671.
264. Fedorak RN, Field M, Chang EB. Treatment of diabetic diarrhea with clonidine. Ann Intern Med 1985;102:197-199.
265. Fealey RD, Low PA, Thomas JE. Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clin Proc 1989;64:617-628.
266. Watkins PJ. Facial sweating after food: a new sign of diabetic autonomic neuropathy. BMJ 1973;1:583-587.
267. Stuart DD. Diabetic gustatory sweating. Ann Intern Med 1978;89:223-224.
268. Freeman R. Treatment of orthostatic hypotension. Semin Neurol 2003;23: 435-442.
269. Snape WJ, Jr., Battle WM, Schwartz SS, et al. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 1982;96:444-446.
270. Longstreth GF, Malagelada J-R, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med 1977; 86:195-196.
271. Perkel MS, Moore C, Hersh T, et al. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci 1979;24:662-666.
272. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30:1-9.
273. Watts GF, Armitage M, Sinclair J, et al. Treatment of diabetic gastroparesis with oral domperidone. Diabet Med 1985;2:491-492.
274. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94: 1230-1234.
275. Farup CE, Leidy NK, Murray M, et al. Effect of domperidone on the healthrelated quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998;21:1699-1706.
276. Barone JA. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 1999;33:429-440.
277. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. . Engl J Med 1990;322:1028-1031.
278. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-426.
279. Saenz DT, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-2164.
280. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-783.
281. Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C-20C.
282. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999;84:11N-17N.
283. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
284. Zorgniotti AW, LeFleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. . Urol 1985;133:39-41.
285. Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. . Urol 1988;140:66-68.
286. Zentgraf M, Baccouche M, Junemann KP. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine. Urol Int 1988;43:65-75.
287. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction: the Alprostadil Study Group. . Engl J Med 1996; 334:873-877.
288. Witherington R. Suction device therapy in the management of erectile impotence. Urol Clin North Am 1988;15:123-128. 277a. Shaw JE, Abbott CA, Tindle K, et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 1997; 40:299-301. 277b. Restivo DA, Lanza S, Patti F, et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 2002:59:1971-1973.
289. Brown MJ, Martin JR, Asbury AK. Painful diabetic neuropathy: a morphometric study. Arch Neurol 1976;33:164-171.
290. Dyck PJ, Lambert EH, O'Brien PC. Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 1976;28:466-471.
291. Britland ST, Young RJ, Sharma AK, C et al. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990;39:898-908.
292. Llewelyn JG, Gilbey SG, Thomas PK, et al. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy: a clinicopathological study. Brain 1991;114:867-892.
293. Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997;46 [Suppl 2]:S50-S53.
294. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37: 589-596.
295. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991;45:3-9.
296. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. . Engl J Med 1992;326:1250-1256.
297. Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms: a double-blind cross-over study. Br J Clin Pharmacol 1990;30:683-691.
298. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55:915-920.
299. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-144. 288a. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60:1284-1289. 288b. Rowbotham MC, Goli V, Kunz NRT, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004:110:697-706.
300. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-1836.
301. McLean MJ. Gabapentin. Epilepsia 1995;36[Suppl 2]:S73-S86.
302. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004:110:628-638.
303. Rull JA, Quibrera R, Gonzalez-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5:215-218.
304. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977;22:196-199.
305. McCleane GJ. Lamotrigine in the management of neuropathic pain: a review of the literature. Clin J Pain 2000;16:321-326.
306. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988;1:9-11.
307. Jarvis B, Coukell AJ. Mexiletine: a review of its therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691-707.
308. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy: the Mexiletine Study Group. Diabetes Care 1997;20:1594-1597.
309. Stracke H, Meyer UE, Schumacher HE, et al. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992;15:1550-1555.
310. Wright JM, Oki JC, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997;31:29-34.
311. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. . Pain Symptom Manage 1996;12:161-167.
312. Simone DA, Nolano M, Johnson T, et al. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. . Neurosci 1998;18:8947-8959.
313. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med 1991;151:2225-2229.
314. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992;15:159-165.
315. Tandan R, Lewis GA, Badger GB, et al. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care 1992;15:15-18.
316. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63:865-873.
317. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50: 1842-1846.